Market Overview

UPDATE: Stifel Nicolaus Initiates Infinity Pharmaceuticals at Hold; Royalty Burden High

Related INFI
UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014
Benzinga's Top Downgrades

Stifel Nicolaus initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with a Hold rating.

Stifel Nicolaus noted, "Infinity's phosphoinositide-3-kinase (PI3K) inhibitor, IPI-145, has the potential to be a best-in-class drug for one of the most exciting targets in oncology and inflammation treatment. Preclinical data for IPI-145 as well as data from other drugs in development validate the PI3K target in our opinion as one that will provide strong efficacy in tumor resistance and inflammation reduction, while retaining a favorable safety profile. IPI-145 is the only dual PI3K delta and gamma inhibitor currently in clinical trials."

Infinity Pharmaceuticals closed at $17.74 on Thursday.

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (INFI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free